专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明专利

SG10202111095XA ANTI-CD3 ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND CD3 AND CD20, AND USES THEREOF 未知
公开(公告)号：SG10202111095XA
公开(公告)日：2021-11-29
申请号：SG10202111095X
申请日：2013-09-19
申请人： REGENERON PHARMA
发明人： SMITH ERIC , PAPADOPOULOS NICHOLAS
摘要： The present invention provides antibodies that bind to CD3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with high affinity and induce human T cell proliferation. The invention includes antibodies that bind CD3 and induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human CD20. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell tumors expressing CD20. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For example, the antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

42. 发明专利

PL2975051T3 WYIZOLOWANE Z ŁATWOŚCIĄ DWUSWOISTE PRZECIWCIAŁA O FORMACIE NATYWNEJ IMMUNOGLOBULINY 未知
公开(公告)号：PL2975051T3
公开(公告)日：2021-09-20
申请号：PL15181155
申请日：2010-06-25
申请人： REGENERON PHARMA
发明人： DAVIS SAMUEL , SMITH ERIC , MACDONALD DOUGLAS , OLSON KARA LOUISE
IPC分类号： C07K16/06 , A61K39/00 , C07K16/24 , C07K16/28 , C07K16/46

43. 发明专利

SI2975051T1 Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom 未知
公开(公告)号：SI2975051T1
公开(公告)日：2021-08-31
申请号：SI201032069
申请日：2010-06-25
申请人： REGENERON PHARMA
发明人： DAVIS SAMUEL , SMITH ERIC , MACDONALD DOUGLAS , OLSON KARA LOUISE
IPC分类号： C07K16/00 , A61K39/00

44. 发明专利

HUE054257T2 Könnyen izolálható, natív immunglobulin felépítésû bispecifikus antitestek 未知
公开(公告)号：HUE054257T2
公开(公告)日：2021-08-30
申请号：HUE15181155
申请日：2010-06-25
申请人： REGENERON PHARMA
发明人： DAVIS SAMUEL , SMITH ERIC , MACDONALD DOUGLAS , OLSON KARA LOUISE
IPC分类号： C07K16/06 , A61K39/00 , C07K16/24 , C07K16/28 , C07K16/46

45. 发明专利

BR112021010457A2 Anticorpos biespecíficos anti-muc16 x anti cd28 e usos dos mesmos 未知
公开(公告)号：BR112021010457A2
公开(公告)日：2021-08-24
申请号：BR112021010457
申请日：2019-12-18
申请人： REGENERON PHARMA
发明人： CRAWFORD ALISON , ANDREW J MURPHY , HERMANN AYNUR , SKOKOS DIMITRIS , SMITH ERIC , ULLMAN ERICA , GEORGE D YANCOPOULOS , WAITE JANELLE , HABER LAURIC
IPC分类号： C07K16/28 , A61P35/00 , C07K16/30
摘要： anticorpos biespecíficos anti-muc16 x anti-cd28 e usos dos mesmos. a presente invenção fornece moléculas de ligação ao antígeno biespecíficas que compreendem um primeiro domínio de ligação ao antígeno se que liga especificamente a cd28 humano e uma segunda molécula de ligação ao antígeno que se liga especificamente a muc16 humano. em certas modalidades, as moléculas de ligação ao antígeno biespecíficas da presente invenção têm capacidade de inibir o crescimento de tumores que expressam muc16, como tumores de ovário. as moléculas de ligação ao antígeno biespecíficas da invenção são úteis para o tratamento de doenças e distúrbios nos quais uma resposta imunológica alvo induzida ou de regulação crescente é desejada e/ou terapeuticamente benéfica.

46. 发明专利

MA50374B1 Compositions d'anticorps pour le traitement de tumeurs 未知
公开(公告)号：MA50374B1
公开(公告)日：2021-06-30
申请号：MA50374
申请日：2015-03-18
申请人： REGENERON PHARMA
发明人： THURSTON GAVIN , SMITH ERIC , KIRSHNER JESSICA R , DAVIS SAMUEL , VARGHESE BINDU
IPC分类号： C07K16/28 , A61K39/395
摘要： La présente invention propose des anticorps bispécifiques qui se lient au cd3 et aux antigènes tumoraux et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps bispécifiques de l'invention présentent des fonctions effectrices réduites et ont un profil de liaison unique vis-à-vis des récepteurs fcy. Les anticorps bispécifiques sont conçus pour induire efficacement la destruction des cellules tumorales par les lymphocytes t. Selon certains modes de réalisation, la présente invention propose des molécules bispécifiques de liaison à l'antigène comprenant un premier domaine de liaison à l'antigène qui se lie spécifiquement au cd3 humain, une seconde molécule de liaison à l'antigène qui se lie spécifiquement au cd20 humain, et un domaine fc qui lie les récepteurs fcy avec un motif de reliure. Dans certains modes de réalisation, les molécules de liaison d'antigène bispécifiques de la présente invention sont capables d'inhiber la croissance de cellules b ou de tumeurs de mélanome exprimant cd20. Les anticorps bispécifiques de l'invention sont utiles pour le traitement de divers cancers ainsi que d'autres maladies et troubles liés au cd20.

47. 发明专利

AU2019405747A1 Bispecific anti-CD28 x anti-CD-22 antibodies and uses thereof 未知
公开(公告)号：AU2019405747A1
公开(公告)日：2021-06-17
申请号：AU2019405747
申请日：2019-12-18
申请人： REGENERON PHARMA
发明人： MURPHY ANDREW J , SKOKOS DIMITRIS , WAITE JANELLE , ULLMAN ERICA , HERMANN AYNUR , SMITH ERIC , OLSON KARA , WEI JOYCE , YANCOPOULOS GEORGE D
IPC分类号： A61K39/395 , A61P35/02 , C07K16/28 , C07K16/30
摘要： The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen- binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.

48. 发明专利

AU2016242866B2 Heavy chain constant regions with reduced binding to FC gamma receptors 未知
公开(公告)号：AU2016242866B2
公开(公告)日：2021-06-03
申请号：AU2016242866
申请日：2016-03-30
申请人： REGENERON PHARMA
发明人： DAVIS SAMUEL , SMITH ERIC , ZHANG TONG , PATEL SUPRIYA
IPC分类号： C07K16/28
摘要： The invention provides antibody heavy chain constant regions with a hinge region modified to reduce binding to Fcγ receptors. The modification occurs within positions 233-236 by replacement of natural residues by glycine(s) and/or deletion(s). Such modifications can reduce binding of an antibody bearing such a constant region to Fcγ receptors to background levels. The constant regions can be incorporated into any format of antibody or Fc fusion protein. Such antibodies or fusion proteins can be used in methods of treatment, particularly those in which the mechanisms of action of the antibody or Fc fusion protein is not primarily or at all dependent on effector functions, as is the case when an antibody inhibits a receptor-ligand interaction or agonizes a receptor.

49. 发明专利

HRP20210615T1 PRIPRAVCI ANTITIJELA ZA LIJEČENJE TUMORA 未知
公开(公告)号：HRP20210615T1
公开(公告)日：2021-05-28
申请号：HRP20210615
申请日：2021-04-19
申请人： REGENERON PHARMA
发明人： DAVIS SAMUEL , SMITH ERIC , VARGHESE BINDU , KIRSHNER JESSICA R , THURSTON GAVIN
IPC分类号： C07K16/28 , A61K39/395

50. 发明专利

MA53168A ANTICORPS ANTI-BCMA X ANTI-CD3 BISPÉCIFIQUES ET LEURS UTILISATIONS 未知
公开(公告)号：MA53168A
公开(公告)日：2021-05-26
申请号：MA53168
申请日：2019-07-18
申请人： REGENERON PHARMA
发明人： DELFINO FRANK , DILILLO DAVID , KIRSHNER JESSICA , OLSON KARA , SINESHCHEKOVA OLGA , SMITH ERIC , ZHANG QIAN
IPC分类号： A61K39/00 , A61P35/02 , C07K16/28

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式